The annual Transcatheter Cardiovascular Therapeutics (TCT) meeting brings many cutting-edge technologies to the forefront during its five days of clinical sessions. This is my editor’s choice of...
For functional mitral valve regurgitation, the results of open repair are poor, but the next generation of transcatheter heart valve repair technologies in development may offer new hope for these...
Hospitals constantly try to predict what the future holds when planning new facilities and equipment purchases that need to last for the next decade. Martin Leon, M.D., attempted to answer that...
Edwards Lifesciences Corporation announced three-year results of a pivotal clinical study of inoperable patients with severe aortic stenosis treated with the Edwards Sapien transcatheter heart...
Direct Flow Medical Inc. announced that its DISCOVER CE mark trial met its primary mortality endpoint. The study also demonstrated that greater than 95 percent of patients had mild or less aortic...
The Transcatheter Cardiovascular Therapeutics (TCT) conference showcases key advancements being made in interventional cardiology, focusing this year on the next generation of drug-eluting stents...
October 12, 2012 — Boston Scientific announced it has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus valve system in up to 120...
Medtronic Inc. announced it has received CE mark for its Medtronic CoreValve Evolut 23 mm valve, its latest self-expanding transcatheter aortic valve implantation (TAVI) system.
Cardiologists are restricting the use of transcatheter aortic valve implantation (TAVI) to very old or very sick patients at high surgical risk, according to research presented at the European...
Medtronic has reached two clinical program milestones for its CoreValve system in the United States. It completed enrollment in its study of high-risk patients in its CoreValve U.S. Pivotal...
